The University of Southampton
University of Southampton Institutional Repository

ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia

ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia
Hydroxyurea (HU) has been used for more than 10 years in children severely affected with sickle cell disease (SCD) to reduce the number of painful episodes. Short- to medium-term tolerance of the drug is good.1-3 Concern remains, however, about the long-term safety of the drug and, in particular, its leukemogenic potential. Leukemia has been reported in myelodysplastic syndromes after at least 3 to 4 years of exposure to the drug,4-5 so only long-term studies including significant numbers of patients can resolve concern for SCD. So far, 3 studies on long-term effects of HU in SCD children have been published (Table 1).6-8
in situ hybridization, humans, reverse transcriptase polymerase chain reaction, leukemia, sequence deletion, survival rate, chromosomes, adult, non-u.s.gov't, research support, fluorescence, bcr-abl, myeloid, female, aged, human, 80 and over, fusion proteins, fusion, protein, mortality, pair 9, male, epidemiology, survival, adolescent, chronic, oncogene proteins, letter, base sequence, proteins, genetics, metabolism, middle aged, child
0006-4971
2879-2880
de la Fuente, Josu
205a707f-c4dc-441d-99a3-83a738b4b47e
Merx, Kirsten
a1e54751-ac5f-45be-bcc9-983991158f57
Steer, E. Joanna
ba2647f6-1399-4d19-92cb-1c09671e4681
Müller, Martin
d9c63291-7d2c-44aa-86d4-4fa740354cc6
Szydlo, Richard M.
21106840-5ee6-4c9f-85ef-20050f83d8d4
Maywald, Ole
735f923f-99f3-4ee6-abbf-5456cc945dd8
Berger, Ute
a343755b-a56e-413d-9f14-a0d70f9b4597
Hehlmann, Rüdiger
790dac9f-3d0a-4388-b038-b5bbd07359c4
Goldman, John M.
2632cc83-5866-46bd-914d-8450157fe689
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Melo, Junia V.
0e816e85-ca9f-4a79-9c6f-91ce2279694c
Hochhaus, Andreas
b37b9b7d-85ff-455e-994d-fcc2adf94088
de la Fuente, Josu
205a707f-c4dc-441d-99a3-83a738b4b47e
Merx, Kirsten
a1e54751-ac5f-45be-bcc9-983991158f57
Steer, E. Joanna
ba2647f6-1399-4d19-92cb-1c09671e4681
Müller, Martin
d9c63291-7d2c-44aa-86d4-4fa740354cc6
Szydlo, Richard M.
21106840-5ee6-4c9f-85ef-20050f83d8d4
Maywald, Ole
735f923f-99f3-4ee6-abbf-5456cc945dd8
Berger, Ute
a343755b-a56e-413d-9f14-a0d70f9b4597
Hehlmann, Rüdiger
790dac9f-3d0a-4388-b038-b5bbd07359c4
Goldman, John M.
2632cc83-5866-46bd-914d-8450157fe689
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Melo, Junia V.
0e816e85-ca9f-4a79-9c6f-91ce2279694c
Hochhaus, Andreas
b37b9b7d-85ff-455e-994d-fcc2adf94088

de la Fuente, Josu, Merx, Kirsten, Steer, E. Joanna, Müller, Martin, Szydlo, Richard M., Maywald, Ole, Berger, Ute, Hehlmann, Rüdiger, Goldman, John M., Cross, Nicholas C.P., Melo, Junia V. and Hochhaus, Andreas (2001) ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood, 98 (9), 2879-2880. (doi:10.1182/blood.V98.9.2879).

Record type: Article

Abstract

Hydroxyurea (HU) has been used for more than 10 years in children severely affected with sickle cell disease (SCD) to reduce the number of painful episodes. Short- to medium-term tolerance of the drug is good.1-3 Concern remains, however, about the long-term safety of the drug and, in particular, its leukemogenic potential. Leukemia has been reported in myelodysplastic syndromes after at least 3 to 4 years of exposure to the drug,4-5 so only long-term studies including significant numbers of patients can resolve concern for SCD. So far, 3 studies on long-term effects of HU in SCD children have been published (Table 1).6-8

This record has no associated files available for download.

More information

Published date: 1 November 2001
Keywords: in situ hybridization, humans, reverse transcriptase polymerase chain reaction, leukemia, sequence deletion, survival rate, chromosomes, adult, non-u.s.gov't, research support, fluorescence, bcr-abl, myeloid, female, aged, human, 80 and over, fusion proteins, fusion, protein, mortality, pair 9, male, epidemiology, survival, adolescent, chronic, oncogene proteins, letter, base sequence, proteins, genetics, metabolism, middle aged, child

Identifiers

Local EPrints ID: 24680
URI: http://eprints.soton.ac.uk/id/eprint/24680
ISSN: 0006-4971
PURE UUID: 3f593086-5914-4b4b-9c28-3ee44151cc51
ORCID for Nicholas C.P. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 05 Apr 2006
Last modified: 16 Mar 2024 03:23

Export record

Altmetrics

Contributors

Author: Josu de la Fuente
Author: Kirsten Merx
Author: E. Joanna Steer
Author: Martin Müller
Author: Richard M. Szydlo
Author: Ole Maywald
Author: Ute Berger
Author: Rüdiger Hehlmann
Author: John M. Goldman
Author: Junia V. Melo
Author: Andreas Hochhaus

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×